Conversation Starters of the Week

Every week, Rommil Santiago shares interesting LinkedIn posts that he runs across to help spark ideas and conversation. Here are this week’s finds:

1) From Ronny Kohavi

“In software, we often abort A/B tests (randomized controlled experiments) that are clearly negative and hurt users (, but we never abort a positive experiment; if anything, we would either start a larger experiment or a replication run. 

Merck announced Oct 1st that the results of Molnupiravir, an Oral Antiviral drug for COVID-19, are so good, they cut the trial short (

Health care is known to move slow, but there is also a push for more evidence-based health care. Is this such an example where we could do better by continuing the trial, and/or running a larger trial UNTIL Emergency Use Authorization is given? I’d love to hear from experts about why this decision makes sense in health care but not in the software world.”

Join the conversation:

2) From Jonny Longden

“I know it’s an old debate, but it’s an interesting one nevertheless: should CRO be called that or should it be called something else?

It’s not just semantics and detail – the issue is much deeper.

The fact is that most people view CRO as a kind of hacking and tactical ‘tweaking’ of small stuff, which is 100% wrong and means they are missing out on massive potential benefit.

What it really is, is simply using the scientific method to de-risk everything you do through proof. This can fuel big things and it can also improve a tonne of stuff which isn’t conversion.

So no, the name doesn’t do it any favours.”

Join the conversation:

3) From Aditi Gupta

“Product growth is not just top funnel acquisition, it happens at multiple touchpoints through out the customer journey. In my session for Product Drive this year I will talk about the 6 levers of growth and share some best practises around them.
Sign up here –

Join the conversation:

4) From Jason Vana

“Can you fit your brand strategy on 1 page?

If not, it’s likely too complex.”

Join the conversation:–Hao

5) From Matt Scaysbrook

“I’ve spoken fairly vociferously in recent weeks about the level of criticism of “sub-par” CRO / experimentation work, and that that is not the way to develop an inclusive & better-informed industry.

None of us are so good that we are above mistakes. And none of us are so well-informed that we don’t misunderstand, or misapply subject-matter knowledge at times.

So let’s down the pitchforks & the flaming torches, acknowledge that there will always be mistakes, oversights & errors, and focus on what brings us together as an industry, not what divides us.”

Join the conversation:

Connect with Experimenters from around the world

We’ll highlight our latest members throughout our site, shout them out on LinkedIn, and for those who are interested, include them in an upcoming profile feature on our site.

Rommil Santiago